TNF-α Inhibitor Associated Psoriasis in Rheumatoid Arthritis and Inflammatory Bowel Disease Patients: A Disproportionality Analysis Using the FDA Adverse Event Reporting System
Restricted accessLetterFirst published online January, 2026
TNF-α Inhibitor Associated Psoriasis in Rheumatoid Arthritis and Inflammatory Bowel Disease Patients: A Disproportionality Analysis Using the FDA Adverse Event Reporting System
XieWXiaoSHuangHZhangZ. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front Immunol. 2022;13:847160. doi:10.3389/fimmu.2022.847160
2.
JoulfayanHMakuntsTAbagyanR. Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data. Sci Rep. 2023;13(1):10448. doi:10.1038/s41598-023-37010-6
SeneschalJMilpiedBVergierBLepreuxSSchaeverbekeTTaïebA. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br J Dermatol. 2009;161(5):1081-1088. doi:10.1111/j.1365-2133.2009.09329.x
5.
RahierJFBucheSPeyrin-BirouletL, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048-1055. doi:10.1016/j.cgh.2010.07.022
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
